Skip to Content
Merck
  • Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.

Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.

Antimicrobial agents and chemotherapy (2008-06-04)
Amélie Carrër, Laurent Poirel, Haluk Eraksoy, A Atahan Cagatay, Selim Badur, Patrice Nordmann
ABSTRACT

The first outbreak of carbapenem-resistant Klebsiella pneumoniae isolates producing the plasmid-encoded carbapenem-hydrolyzing oxacillinase OXA-48 is reported. The 39 isolates belonged to two different clones and were collected at the University Hospital of Istanbul, Turkey, from May 2006 to February 2007, and they coproduced various beta-lactamases (SHV-12, OXA-9, and TEM-1 for clone A and CTX-M-15, TEM-1, and OXA-1 for clone B).

MATERIALS
Product Number
Brand
Product Description

Supelco
Trimethoprim, VETRANAL®, analytical standard
Sigma-Aldrich
Trimethoprim, ≥99.0% (HPLC)
Sigma-Aldrich
Trimethoprim, ≥98.5%
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Supelco
Norfloxacin, VETRANAL®, analytical standard
Supelco
Ofloxacin, VETRANAL®, analytical standard
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Ofloxacin, fluoroquinolone antibiotic
Sigma-Aldrich
Amoxicillin, 95.0-102.0% anhydrous basis
Sigma-Aldrich
Nalidixic acid, ≥98%
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)